Vas Narasimhan (Photographer: Simon Dawson/Bloomberg via Getty Images)

#ACC21: No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

If No­var­tis learned one thing from its in­ter­ac­tion with the FDA over its lat­est heart fail­ure ap­proval for En­tresto, it was that miss­ing a pri­ma­ry end­point may not be the nail in the cof­fin. Now, En­tresto has missed again on a late-stage study in high-risk heart pa­tients, and it’s al­ready sow­ing the seeds for a path for­ward re­gard­less.

No­var­tis’ En­tresto couldn’t best stan­dard-of-care ACE in­hibitor ramipril in staving off a com­pos­ite of deaths and heart fail­ure events in pa­tients with left ven­tric­u­lar sys­tolic dys­func­tion and/or pul­monary con­ges­tion who have had a pri­or heart at­tack, ac­cord­ing to topline da­ta from the Phase III PAR­ADISE-MI study re­vealed Sat­ur­day at the vir­tu­al Amer­i­can Col­lege of Car­di­ol­o­gy meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.